| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5604213 | JANSSEN BIOTECH | 17-substituted steroids useful in cancer treatment |
Feb, 2014
(10 years ago) | |
| US8822438 | JANSSEN BIOTECH | Methods and compositions for treating cancer |
Aug, 2027
(3 years from now) | |
Zytiga is owned by Janssen Biotech.
Zytiga contains Abiraterone Acetate.
Zytiga has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zytiga are:
- US5604213
Zytiga was authorised for market use on 28 April, 2011.
Zytiga is available in tablet;oral dosage forms.
Zytiga can be used as use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel, use in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer.
Drug patent challenges can be filed against Zytiga from 29 April, 2015.
The generics of Zytiga are possible to be released after 24 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-765) | Feb 07, 2021 |
| New Indication(I-663) | Dec 10, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2016 |
Drugs and Companies using ABIRATERONE ACETATE ingredient
NCE-1 date: 29 April, 2015
Market Authorisation Date: 28 April, 2011
Treatment: Use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel; Use in combination with...
Dosage: TABLET;ORAL
ZYTIGA family patents
